Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
A Phase II Randomized, Double-Blind Trial of Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab Versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma With No Evidence of Disease
Sponsor: Prof. Dr. med. Dirk Schadendorf
A PHASE2 clinical study on Malignant Melanoma, this trial is completed. The trial is conducted by Prof. Dr. med. Dirk Schadendorf and has accumulated 11 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
May 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prof. Dr. med. Dirk Schadendorf
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Buxtehude, Germany , Dresden, Germany , Erfurt, Germany , Essen, Germany , Gera, Germany , Hanover, Germany , Heidelberg, Germany , Heilbronn, Germany , Kiel, Germany and 10 more locations